A study suggested that nirmatrelvir-ritonavir (Paxlovid) and molnupiravir (Lagevrio) both reduced the risk for COVID hospitalization or death during the Omicron era
What's best for high-risk patients?
Medpage Today® surveys are polls of those who choose to participate and are, therefore, not valid statistical samples, but rather a snapshot of what your colleagues are thinking